Pepdexpepdex
Stack
โ„– 066

Amycretin

Novo Nordisk's single-molecule GLP-1 + amylin co-agonist. Phase 1/2 in oral and subcutaneous formulations. The pharmacological consolidation of the Semaglutide + Cagrilintide concept into one peptide.

Fat Loss
Evidence: Moderate

Amycretin: Novo Nordisk's single-molecule GLP-1 + amylin co-agonist. Phase 1/2 in oral and subcutaneous formulations. The pharmacological consolidation of the Semaglutide + Cagrilintide concept into one peptide. Amycretin is Novo Nordisk's experiment in putting Semaglutide and Cagrilintide together as one molecule instead of two separate drugs.

FDA โ“˜
Not approved
WADA
Not banned
Typical dose
Trial doses still being established
Half-life โ“˜
~5-7 days (sub-q form)
Route โ“˜
Subcutaneous (sub-q form) or oral (oral form)
Schedule
Once weekly (sub-q) or once daily (oral)
In plain English

Amycretin is Novo Nordisk's experiment in putting Semaglutide and Cagrilintide together as one molecule instead of two separate drugs. Activates GLP-1 + amylin in a single injection. They're testing both an oral pill and a weekly injection. Phase 1/2 only, not available yet.

Status & legalityWhat do these mean? โ†’
Natty? โ“˜
Not natty
FDA โ“˜
Not approved

Investigational. Phase 1/2 trials by Novo Nordisk in oral and subcutaneous formulations.

Compounding โ“˜
Investigational

In clinical trials, not yet approved for prescription.

WADA โ“˜
Not listed
Prescribed โ“˜

Trial access only.

Who it's for

  • โ†’Trial participants in obesity studies
  • โ†’Followers of Novo's next-generation pipeline
  • โ†’Educational reference for dual co-agonist design

What to expect

  1. Week 1

    Appetite drops. Some early-trial users reported faster onset than Semaglutide alone.

  2. Week 4

    First titration step.

  3. Week 8

    Phase 1b data showed weight loss outperforming Semaglutide-monotherapy comparators.

Looking at Amycretin? Your next 3 steps

  1. 1Work out your syringe units

    Vial size + BAC water turns into the exact units to draw for Amycretin.

    Open calculator โ†’
  2. 2See what to stack & monitor

    The companion supplements and the bloodwork worth tracking on this kind of protocol.

    Bloodwork guide โ†’
  3. 3Save it & ask the Coach

    A free account gets you Coach questions every day, free; membership saves your stack and makes the Coach stack-aware.

    Create free account โ†’

How it works (mechanism)

Single-molecule co-agonist, activates GLP-1 AND amylin receptors simultaneously. Pharmacological consolidation of the CagriSema concept into one peptide instead of two.

Dosing protocol

Members only

Stacks well with

Members only

Side effects

01Nausea (less than Semaglutide monotherapy in early data)
02Reduced appetite
03Constipation

When NOT to use

  • โš MTC / MEN-2 history
  • โš Pancreatitis history
  • โš Pregnancy / nursing

Bloodwork to monitor

  • โ€ข Lipid panel
  • โ€ข A1C
  • โ€ข ALT/AST

Common mistakes

  • โ€ข Expecting trial-grade material from community vendors
  • โ€ข Treating it as available-now (Phase 1/2 still)
  • โ€ข Comparing oral form dosing to sub-q form dosing

What it actually is

Amycretin is Novo Nordisk's attempt to put GLP-1 and amylin agonism into a single molecule, rather than combining two drugs the way CagriSema does. It exists in both a weekly injectable and a daily oral form and is in early clinical development โ€” phase 1 and 2. It is not approved anywhere, and the reported weight loss in early trials was large enough to attract a great deal of attention on a very small evidence base.

GLP-1 and amylin produce satiety through different routes โ€” GLP-1 through the classic incretin pathway, amylin through the brainstem โ€” and hitting both produces more appetite suppression than either alone. CagriSema demonstrates that with two molecules. Amycretin does it with one, which simplifies manufacturing, dosing and the regulatory path considerably. The oral programme matters for the same reason it matters for any of these drugs: injection is the biggest adherence barrier in the class.

Forms, and which is which

Clinical trial supply, weekly injectionThe only lawful route

Phase 1b/2a reported roughly 24% weight loss at 36 weeks at the highest doses tested. Identity, dose and monitoring known only here.

Verdict: The only defensible access.

Clinical trial supply, daily oralThe oral programme

A separate first-in-class oral programme with its own exposure profile. Not interchangeable with the injection at the same dose.

Verdict: A different drug exposure, not a convenience swap.

Products sold as amycretinNothing lawful

No approved product exists to compare against; identity and potency cannot be verified.

Verdict: Unverifiable contents outside any lawful route.

CagriSemaThe two-molecule version

Semaglutide plus cagrilintide, the same pathway combination with phase 3 data behind it.

Verdict: The same idea, further along, in two molecules.

What it is claimed to do, graded

Large weight loss in early trialsModerate

A phase 1b/2a trial published in the Lancet in 2025 reported roughly 24% weight loss at 36 weeks at the highest dose. A striking number from an early-phase trial in a small population.

A single molecule can do what CagriSema does with twoLimited

The pharmacological premise, supported by the early data. No head-to-head against CagriSema exists.

An oral form works at these dosesLimited

A first-in-class oral programme has reported. Early, and the tolerability picture is not settled.

Better tolerated than semaglutide monotherapyLimited

Suggested in early data and repeated widely. No head-to-head trial establishes it.

Safe for extended useNone shown

Phase 1 and 2 only. Nothing establishes durability or long-term safety, and 36 weeks in a small trial is not a safety profile.

Grades describe how much human evidence exists for that specific claim, not whether it will work for you or whether it is safe.

Pros and cons

Pros
  • โ€ข A genuinely elegant consolidation โ€” one molecule for a combination that currently needs two
  • โ€ข Early weight-loss figures are among the largest reported for any obesity drug at this stage
  • โ€ข Both injectable and oral programmes are running
  • โ€ข Published in the Lancet rather than announced only by press release
Cons
  • โ€ข Phase 1 and 2 only โ€” two indexed randomised-trial records in total
  • โ€ข The headline weight-loss figure comes from a small early-phase trial and will not necessarily survive phase 3
  • โ€ข Not approved anywhere; access is trial-only
  • โ€ข Gastrointestinal effects are common in the class and dose-dependent
  • โ€ข Nothing sold outside a trial can be verified

When to stop

  • โ€ข Severe persistent abdominal pain radiating to the back
  • โ€ข Vomiting that prevents keeping fluids down
  • โ€ข A new neck lump, hoarseness or difficulty swallowing
  • โ€ข Appetite suppression severe enough that protein intake has collapsed
  • โ€ข Pregnancy

Interactions

Insulin or sulfonylureasCaution

Additive glucose lowering expected from the GLP-1 arm. No approved interaction labelling exists.

Other GLP-class drugs or amylin analogsAvoid

Amycretin already does both jobs. Adding either duplicates half of it.

Oral medications generallyMonitor

Delayed gastric emptying can alter absorption rate.

AlcoholCaution

Compounds nausea and hypoglycaemia risk where intake is already low.

Resistance training and adequate proteinCompatible

General weight-loss guidance, not an amycretin trial finding.

Is this for you?

Probably worth reading further if
  • โ€ข Participation in an authorised clinical trial is the only context in which this is lawfully available
  • โ€ข Anyone following where single-molecule incretin combinations are heading
Skip it if
  • โ€ข You want an approved medicine with a known safety profile
  • โ€ข Personal or family history of medullary thyroid carcinoma or MEN-2
  • โ€ข You are pregnant or nursing
  • โ€ข You are treating an early-phase headline number as a settled result

The one number

Roughly 24% weight loss at 36 weeks at the highest dose, in a phase 1b/2a trial
Lancet, 2025 (PMID 40550231)

Sources for the claims above

  • Amycretin, a unimolecular GLP-1 and amylin receptor agonist, phase 1b/2a
    Lancet, 2025
  • First-in-class safety, tolerability, pharmacokinetics and pharmacodynamics
    Lancet, 2025
  • Effect of amycretin on weight and metabolic markers
    EBioMedicine, 2025

Drug & supplement interactions

  • โš Combined GLP-1 + amylin warnings: insulin dose reduction; slowed oral absorption
  • โš Trial-only, full interaction profile not yet published
Free, no account needed

New to Amycretin? Grab the starter checklist.

Drop your email and we'll send the one-page starter checklist beginners actually need first. No account needed.

No spam, and we never sell your email. Just the checklist. Email support@pepdex.co to opt out any time.

AI Coach, live sample
Member answer
is 250mcg of bpc enough for a knee injury?
For a knee, is the standard working dose and a solid place to start. The trick with BPC is consistency, give it weeks, not days. , run it , and don't drop below , results tend to fall off under that line. If nothing's moved by week 3, that's when earns its place.
how much bac water for a 10mg reta vial?
is the standard play for a 10 mg reta vial. That gives you , clean unit math across the whole titration: on a 100-unit insulin syringe. Run instead if you want fewer, more concentrated shots. Most people titrate up over , and that mix keeps the numbers cleanest.
what should i track on bloodwork for tirzepatide?
Lipid panel, ALT/AST (liver enzymes), and an A1C, baseline before you start then every 3 months. If you've got metabolic-syndrome history, add fasting glucose and insulin so you can actually watch insulin sensitivity improve. You don't need a big hormone panel for a GLP-1.

Numbers redacted in this preview. Members get the full answer, on their own stack.

Ask the Coach anything about Amycretin or your own stack. This is it working.

Trained only on Pepdex content. Does the dose math, flags interactions, knows your stack. Won't push vendors, won't pretend to be a doctor.

Unlock the full Coach, from $4.99/week โ†’

Frequently asked

What is Amycretin?+
Amycretin is Novo Nordisk's experiment in putting Semaglutide and Cagrilintide together as one molecule instead of two separate drugs. Activates GLP-1 + amylin in a single injection. They're testing both an oral pill and a weekly injection. Phase 1/2 only, not available yet.
Is Amycretin FDA approved?+
Investigational. Phase 1/2 trials by Novo Nordisk in oral and subcutaneous formulations.
Is Amycretin legal?+
Amycretin is not FDA-approved, so there is no approved prescription version. Most supply is sold as "research only" by peptide vendors. A compounding pharmacy may only use substances the FDA permits for compounding, and many research peptides are not permitted โ€” do not assume a compounded prescription is available. Possession is generally not criminalized but distribution without authorization may be. Verify local laws.
Is Amycretin banned by WADA?+
Amycretin is not currently on the WADA prohibited list.
Are you still natty after taking Amycretin?+
No. Amycretin is a performance-enhancing peptide and would disqualify a strict natty claim.
Do doctors prescribe Amycretin?+
Trial access only.
What's the typical dose of Amycretin?+
Dosing depends on your goal, experience, and tolerance. The full Amycretin protocol (dose, frequency, and how to titrate) is in the members section on the entry page.
What are the side effects of Amycretin?+
Common side effects include: Nausea (less than Semaglutide monotherapy in early data); Reduced appetite; Constipation. Less common effects and full safety details are on the entry page.
How long until Amycretin starts working?+
Appetite drops. Some early-trial users reported faster onset than Semaglutide alone.
What can you stack with Amycretin?+
Amycretin is commonly combined with complementary compounds. The full stacking protocol (what to pair, dosing, and timing) is in the members section on the entry page.
Where do people get Amycretin?+
Pepdex does not sell, ship, or recommend suppliers. Amycretin is not FDA-approved; prescription versions require licensed clinical care, and "research only" markets carry real legal and quality risks. /coa explains how to verify a Certificate of Analysis and /guides/scam-vendor-spotting covers the red flags.
Amycretin vs Retatrutide, which is better?+
Amycretin vs Retatrutide: Novo's GLP-1 + amylin co-agonist vs Lilly's GLP-1 + GIP + glucagon triple agonist. The two most-watched next-generation obesity compounds, both pre-approval. Full head-to-head comparison: https://pepdex.co/compare/amycretin-vs-retatrutide

Common questions about Amycretin

Head-to-head with Amycretin

Compare
Amycretin vs Retatrutide โ†’

Tracked alongside Amycretin

Same goal, different aisle โ€” each graded on its own evidence in the Pepdex catalog.

Whey protein โ†’
muscle preservation is the open question on any GLP-1 run
Electrolytes โ†’
appetite suppression cuts fluid and sodium intake with it
Fiber โ†’
the constipation answer that shows up in every GLP-1 thread
Metformin โ†’
the prescription neighbour people compare these protocols against

More in Fat Loss

โ„– 009
Tirzepatide

Strong weight loss with a cleaner side effect profile than semaglutide. A dual agonist (GLP-1 + GIP), FDA-approved as Mounjaro / Zepbound.

โ„– 010
Semaglutide

The original weight-loss wave, sold as Ozempic / Wegovy. A GLP-1 agonist.

โ„– 003
Retatrutide

Triple agonist (GLP-1 + GIP + glucagon) from Eli Lilly. In trials it outperforms Tirzepatide for weight loss.

โ„– 059
Liraglutide (Saxenda / Victoza)

Daily GLP-1 receptor agonist. FDA-approved 2010 (Victoza, T2D) and 2014 (Saxenda, obesity). The first wave of modern GLP-1 weight-loss therapy and direct predecessor to Semaglutide.